0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Factor VIII"

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
From
EUR$2,750USDGBP
Hemophilia Market - Forecasts from 2023 to 2028 - Product Thumbnail Image

Hemophilia Market - Forecasts from 2023 to 2028

  • Report
  • December 2023
  • 143 Pages
  • Global
From
EUR$3,560USDGBP
EUR$4,450USDGBP
Hemophilia a (Factor Viii Deficiency) - Global Clinical Trials Review, 2024 - Product Thumbnail Image

Hemophilia a (Factor Viii Deficiency) - Global Clinical Trials Review, 2024

  • Clinical Trials
  • February 2024
  • 406 Pages
  • Global
From
EUR$2,500USDGBP
Hemophilia A and B - Epidemiology Forecast to 2030 - Product Thumbnail Image

Hemophilia A and B - Epidemiology Forecast to 2030

  • Report
  • October 2021
  • 54 Pages
  • Global
From
EUR$3,995USDGBP
Loading Indicator

The Factor VIII market is a segment of the hematological drugs market, which includes drugs used to treat blood-related disorders. Factor VIII is a protein that helps blood to clot, and is used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. Factor VIII is typically administered intravenously, and is available in both recombinant and plasma-derived forms. The Factor VIII market is highly competitive, with a number of companies offering products. These include Novo Nordisk, Pfizer, Bayer, CSL Behring, and Shire. Additionally, there are several smaller companies that offer Factor VIII products, such as Octapharma, Kedrion, and Biotest. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more